FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
本文は利用できません。元の情報源をご確認ください。
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.